TY - T1的女性有多发性硬化症与生殖相关的里程碑?乔(4884)JF -神首页经-神经学六世- 96 - 15补充SP - 4884 AU - Burcu Zeydan AU -伊丽莎白·j·阿特金森盟Delana m . Weis AU -史密斯Carin y盟莉莉安娜Gazzuola罗卡AU -沃尔特·罗卡盟b .马克Keegan AU -布莱恩·g·Weinshenker盟Kejal Kantarci AU - Orhun h . Kantarci Y1 - 2021/04/13 UR - //www.ez-admanager.com/content/96/15_Supplement/4884.abstract N2 -目的:比较生殖之间的历史特征的女性多发性硬化症(MS)和控制女性。背景:生殖周期从月经初潮自然绝经常常标志着活跃的炎性疾病时期女士之间的关系性荷尔蒙和免疫系统可能在疾病过程中起着重要的作用在女性MS.Design /方法:病例对照研究的女性和年龄女士控制女性以人群为基础的队列。月经初潮年龄,足月怀孕和不完整的,更年期绝经年龄和类型比较在137年与MS和396匹配控制女性绝经后妇女。结果:女性月经初潮年龄相似与女士和控制女性(中位数、四分位范围(差);女士13年12 - 13.2;控制12年,12 - 13;p = 0.306)。较低数量的女士怀孕的女性比控制女性(中位数,差;女士2、1 - 3;控制3、2 - 4;p = 0.001)和足月怀孕数量低于控制女性(平均差; MS 2, 1–3; controls 3, 2–3; p<0.001). Age at menopause was not different between MS and controls (median, IQR; MS 49 years, 44.5–52; controls 50 years, 43–52; p=0.791). Age at natural menopause was similar between MS and controls as well (median, IQR; MS 50 years, 48–52; controls 51 years, 49–53; p=0.476). Non-natural menopause was more frequent in women with MS (40.7%) compared to control women (30.1%) (p=0.030).Conclusions: The natural reproductive milestones, age at menarche and age at natural menopause, were not different between women with MS and controls. The age at natural menopause was similar to previous studies on MS and to the mean age of 51 in Western populations. Overall, MS does not seem to directly impact the natural reproductive milestones in women. However, in addition to surgical menopause, immunomodulation may be associated with the higher frequency of non-natural menopause in MS.Disclosure: The institution of Dr. Zeydan has received research support from National Institutes of Health. Elizabeth Atkinson has nothing to disclose. Delana Weis has nothing to disclose. Carin Smith has nothing to disclose. The institution of an immediate family member of Liliana Gazzoula Rocca has received research support from National Institute on Aging - NIH. The institution of an immediate family member of Liliana Gazzoula Rocca has received research support from National Heart, Lung, and Blood Institute - NIH. The institution of Dr. Rocca has received research support from National Institute on Aging - NIH. The institution of Dr. Rocca has received research support from National Heart, Lung, and Blood Institute - NIH. Dr. Keegan has received publishing royalties from a publication relating to health care. Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viela Bio. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Group (Chugai, Genentech, Roche). The institution of Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care. Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving as a speaker at internal meeting with Genentech. The institution of Dr. Kantarci has received research support from Eli Lilly. The institution of Dr. Kantarci has received research support from NIH. The institution of Dr. Kantarci has received research support from ADDF. Dr. Kantarci has nothing to disclose. ER -